Lobeglitazone
As of the edition of 20 October 2026, Lobeglitazone is a small molecule: marketed, first approved in 2013 (KR); acts on PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- First approved
- 4 July 2013 (KR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Chong Kun Dang Pharmaceutical
- Registered trials
- 30, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Digestive system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Lobeglitazone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | P37231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 18 | 16 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 5 | 3 | 0 | 0 |
| Phase 4 | 5 | 3 | 1 | 0 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Chong Kun Dang Pharmaceutical | Originator and Lead sponsor of trials | 2007 to now |